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in 10% of patients with vitreous haemorrhage average cost of which was 10% of 
616EUR/operation. It was assumed that surgical treatment (trabeculectomy, Seton 
operation or cyclophotocoagulation) was applied in 2% of increased ocular pres-
sure (IOP) patients average cost of which was 196EUR/operation. Pharmacologic 
treatment was assumed to be applied in 98% of the IOP patients cost of which 
was 4EUR/patient. Thus, overall cost of IOP was calculated as 8EUR. The cost of 
arterial thromboembolic events (282EUR) was taken from local sources. The total 
CoD was calculated as 5520EUR in patients treated with ranibizumab where the 
total cost excluding pharmaceutical was estimated as 590EUR (administration cost 
121EUR, monitoring cost 442EUR, adverse event cost 27EUR). ConClusions: In 
DME, the main part of total CoD was consisted of costs of the treatment, followed 
by monitoring costs.
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objeCtives: The introduction of treatment with inhibitors of Vascular Endothelial 
Growth Factor (VEGF) has made possible the treatment of the Retinal Vascular 
Diseases (RVD) for which there was limited therapeutic resources, or even none. 
The objective of this study was to estimate the average annual cost in Italy incurred 
by the National Health Service (NHS) as well as society due to RVD in which there 
is an overexpression of VEGF. Methods: We developed a probabilistic incidence-
based cost of illness model to estimate an aggregate measure of the economic 
burden associated to RVD-induced diseases in terms of direct and indirect costs. A 
systematic literature review was performed in order to extrapolate epidemiological 
and direct cost data for total or partial blindness patient in Italy. Indirect costs were 
calculated as social security costs analyzing a specific database of the National 
Institute of Social Security (INPS). Data were analyzed considering the total services 
provided and the mean cost for two types of benefits: disability pension and attend-
ance allowance. Furthermore, one-way and probabilistic sensitivity analysis with 
5,000 Monte Carlo simulations was performed in order to test the robustness of 
results. Results: RVD with overexpression of VEGF was estimated to affect 0.84% 
of the Italian population (501.128). Direct costs analysis is under review while the 
annual indirect cost per patient for the disability pensions amount to € 3,454 for 
total blindness patient and € 3,157 for partial blindness. For attendance allowance 
was estimated an average cost of € 10,350 for total blindness € 2.397 for partial blind-
ness. ConClusions: This is the first study in which direct costs (incurred by NHS) 
and especially indirect costs (incurred by the Social Security System) were taken 
into account to estimate the overall burden associated with RVD with overexpres-
sion of VEGF in our Country.
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objeCtives: The objective of the study was to estimate the CoD in CRVO, in Turkish 
setting. Methods: An expert panel was held by participation of five ophthalmolo-
gists to discuss the disease management in CRVO. Physicians reviewed the literature, 
discussed the local clinical practices and all cost components; pharmaceuticals, 
treatment administration, monitoring and adverse events. Two different treatment 
options (ranibizumab and dexamethasone) were studied. September-2014 local 
prices for medications and procedures were used as sources. September-2014 EUR 
currency rate (2.8671TL/EUR) was used. Results: The frequency of treatments in a 
year were assumed as 8.8 and 2.0 and the numbers of outpatient visits in a year were 
accepted as 9 and 7 for ranibizumab and dexamethasone, respectively. Common 
adverse events were taken into account. The cost of cataract was accepted as equal 
to the cost of cataract removal operation which is 143EUR and the cost of retinal 
detachment was accepted as the average cost of surgical treatments as 368EUR. It 
was assumed that surgical treatment (trabeculectomy, Seton operation or cyclopho-
tocoagulation) was applied in 2% of increased ocular pressure (IOP) patients (average 
cost 183EUR/operation). Pharmacologic treatment was assumed to be applied in 98% 
of the IOP patients (4EUR/patient). Thus, overall cost of IOP was calculated as 7EUR. 
The total CoD was calculated as 3,823EUR per patients treated with ranibizumab, 
where the cost excluding pharmaceutical was determined as 138EUR. The CoD in 
patients treated with dexamethasone was estimated as 1,195EUR which is lower 
when compared to CoD in patients treated with ranibizumab. Total cost excluding 
pharmaceutical was calculated 240EUR for dexamethasone. ConClusions: In 
CRVO, the cost of treatment formed the major part of the total CoD when compared 
to monitoring, administration and adverse event costs.
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research the most accessible on costs and widespread technology of dental implan-
tation was conducted with zirconia or sandblasted/acid etched titanium implants 
despite their price is much higher than just titanium implants. Ukrainian patients 
pay out-of-pocket for dental implantation and the main task of stakeholders is to 
provide the most effective services. ConClusions: The most expensive was the 
implantation with sandblasted and acid etched titanium implants (p < 0,001) and 
zirconia implants (p < 0,5). Also we revealed that patients were highly motivated to 
pay for dental implantation in order to get the best esthetical result.
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objeCtives: The dental benefit of sugar free gum is scientifically proven. Comparing 
Germany and Finland, both countries show similar health systems as well as dental 
health among the population, but the consumption of sugar free gum is much higher 
in Finland. This paper aims at extrapolating the consumption of sugar free gum in 
Germany to values of Finland to estimate the potential costs savings for the German 
health care system due to a decreased risk of caries by consuming more sugar free 
gum. Methods: Overall dental costs in Germany are identified and the share of 
expenditures due to caries is estimated. The dental benefit of the consumption of 
sugar free gum is quantified as a reduction of the relative risk of caries based on data 
from the literature. Extrapolating the chewing frequencies in Germany to finish values 
and combining these with the dental benefit of consuming sugar free gum allows esti-
mating the potential cost saving due to better dental health for both the statutory and 
private health insurance. Results: The increase of the consumption of sugar free 
gum in Germany leads to a reduced risk for caries and better dental health. Potential 
cost saving amount to 240 M € for the statutory sector and 73 M € for the private 
sector. ConClusions: The overall state of dental health in Germany and Finland is 
similar and the countries show many commonalities with regard to the dental health 
system and overall dental health. By regularly consuming sugar free gum the risk 
of a caries can be reduced and cost savings up to 313 M € for Germany are possible.
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objeCtives: To analyse the direct and indirect medical costs in patients with dia-
betic macular oedema (DMO) or macular oedema secondary to retinal vein occlusion 
(MO-RVO). Methods: This was an observational, cross-sectional, multicenter study 
in adults diagnosed with DMO or MO-RVO in the last 6-12 months in one or both eyes. 
Health resource utilization (HRU) data were collected from diagnosis. Employment 
status of patients and the impact of the disease in their professional life were also 
assessed. Annual direct healthcare costs and indirect costs caused by morbidity were 
estimated by diagnostic group (€ , January 2014). Differences were assessed using 
Chi-square (or Fisher exact), Mann-Whitney or Kruskal-Wallis (Dunn contrast) tests. 
A multivariate regression analysis was used to predict the direct costs. Results: 
The study included 448 subjects (DMO n= 255; MO-RVO n= 193). No differences in age, 
gender or time of observation were found. There was stabilization over time in visual 
acuity and also a reduction in the foveal thickness. There were differences in diagnos-
tic costs: MO-RVO= € 1,856 (95%CI:1,741-1,971), bilateral DMO= € 1,661 (1,512-1,810) and 
unilateral DMO= € 1,401 (1,307-1,494), p< 0.001; and treatment costs (p< 0.001). There 
were also differences in total medical costs: MO-RVO= € 4,639 (3,809-5,469), bilateral 
DMO= € 6,275 (4,889-7,660) and unilateral DMO= € 6,269 (4,209-8,329), p< 0.001. Costs due 
to permanent disability were greater in bilateral DMO (€ 11,712, 95% CI 2,395-21,029) 
than in unilateral DMO (€ 4,284, −516-9,085) and MO-RVO (€ 1,052; −553-2,657), p< 0.05. 
In the regression analysis, the variables associated with health costs were: number 
of hospitalization days and number of visits, time of observation, diagnosis and days 
off work. ConClusions: Patients with bilateral DMO have higher direct healthcare 
costs and indirect costs due to morbidity.
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objeCtives: The objective of the study was to estimate the CoD in DME, in Turkish 
setting. Methods: A panel by participation of seven ophthalmologists was held 
to discuss the disease management in DME. Physicians reviewed the literature, 
discussed the local clinical practices and all cost components; pharmaceuticals, 
treatment administration, monitoring and adverse event. Cost of ranibizumab 
treatment was studied and January 2015 local prices for medications and proce-
dures were used as sources. January 2015 EUR currency rate (2.6785TL/EUR) was 
used. Results: The frequency of treatments and outpatient visits were assumed 
as 7.4 for the first year, 4.0 for the second year, 2.9 for the third year and 1.0 for 
the following years for ranibizumab. Common adverse events were taken into 
account. The cost of cataract was accepted as equal to the cost of cataract removal 
operation which is 153EUR. It was assumed that vitroretinal surgery was applied 
